Photo: Getty Images

Cybersecurity firm Kaspersky Lab has filed a lawsuit targeting the second of two federal bans on its wares. The latest suit goes after language in a defense law explicitly blocking the purchase of Kaspersky products. An earlier suit targets a Homeland Security directive doing the same.

The bigger picture: With the White House reluctant to institute additional sanctions on Russia, White House Cyber Czar Rob Joyce pointed to Kaspersky as an example of the Trump administration taking Russia seriously. While Kaspersky isn't alleged to be involved in the election hacks of 2016, it's hard not to see the actions against the firm in the context of deteriorated relations with Moscow, as part of a growing spat between the two countries.

At the center of the Kaspersky bans are fears Russia could use its products in espionage operations. Media reports suggest U.S. intelligence believe this has already happened when spies reconfigured the malware detection feature of Kaspersky antivirus to search for classified documents. That has never been confirmed by the U.S. government and the company denies witting involvement in any such scheme.

Kaspersky argues, in a Monday filing in D.C. federal court, that the defense authorization serves as an unconstitutional "bill of attainder," a law targeted specifically at an individual or small group.

Go deeper

Trump pushes to expand ban against anti-racism training to federal contractors

Trump speaking at Moon Township, Penns., on Sept. 22. Photo: Mandel Ngan/AFP via Getty Images

President Trump announced late Tuesday that the White House attempt to halt federal agencies' anti-racism training would be expanded to block federal contractors from "promoting radical ideologies that divide Americans by race or sex."

Why it matters: The executive order appears to give the government the ability to cancel contracts if anti-racist or diversity trainings focused on sexual identity or gender are organized. The memo applies to executive departments and agencies, the U.S. military, federal contractors and federal grant recipients.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 9:30 p.m. ET: 31,467,508 — Total deaths: 967,881— Total recoveries: 21,583,915Map.
  2. U.S.: Total confirmed cases as of 9:30 p.m. ET: 6,890,662 — Total deaths: 200,710 — Total recoveries: 2,646,959 — Total tests: 96,612,436Map.
  3. Health: The U.S. reaches 200,000 coronavirus deaths — The CDC's crumbling reputation — America turns against coronavirus vaccine.
  4. Politics: Elected officials are failing us on much-needed stimulus.
  5. Business: Two-thirds of business leaders think pandemic will lead to permanent changes — Fed chair warns economy will feel the weight of expired stimulus.
  6. Sports: NFL fines maskless coaches.
Dan Primack, author of Pro Rata
3 hours ago - Economy & Business

GoodRx prices IPO at $33 per share, valued at $12.7 billion

Illustration: Sarah Grillo/Axios

GoodRx, a price comparison app for prescription drugs at local pharmacies, on Tuesday night raised $1.14 billion in its IPO, Axios has learned.

By the numbers: GoodRx priced its shares at $33 a piece, above its $24-$28 per share offering range, which will give it an initial market cap of around $12.7 billion.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!